Reports Q4 revenue $1.09B, consensus $1.07B. “IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world,” said Jay Mazelsky, President and Chief Executive Officer. “2025 was a pivotal year for the Company, marked by the successful launch of IDEXX Cancer Dx(TM) for canine lymphoma and meaningful adoption of IDEXX inVue Dx well ahead of our initial goals. These innovations represent an important new phase of IDEXX’s growth, expanding the role of diagnostics in earlier disease detection while helping veterinarians improve efficiency and manage workflow complexity. We enter 2026 with an exciting innovation pipeline, expanding instrument and software installed bases, and strong momentum across our global business.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 1
- IDXX Upcoming Earnings Report: What to Expect?
- IDEXX Laboratories: Seamless CEO Transition, Robust Innovation Pipeline, and Strong Execution Support Buy Rating
- Idexx CEO Jonathan Mazelsky to switch to chairman, Michael Erickson to succeed
- Idexx Laboratories announces planned CEO succession and transition